Biomarin Pharmaceutical Inc
BMRN
Company Profile
Business description
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Contact
770 Lindaro Street
San Rafael CA 94901
USAT: +1 415 506-6700
E: ir@bmrn.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
3,401
Biomarin Pharmaceutical Inc News & Analysis
Morningstar Investment Ideas
Stocks
ETFs
- Australian ETFs
- Active Australian Equity ETFs
- Passive Australian Equity ETFs
- Emerging Market Equity ETFs
- Sustainable ETFs
- Active Global Equity ETFs
- Passive Global Equity ETFs
- Active Australian Fixed Interest ETFs
- Passive Australian Fixed Interest ETFs
- Active Australian Listed Property ETFs
- Passive Australian Listed Property ETFs
- Active Global Fixed Interest ETFs
- Passive Global Fixed Interest ETFs
- Active Global Infrastructure ETFs
- Passive Global Infrastructure ETFs
- Active Global Property ETFs
- Passive Global Property ETFs
Funds
- Active Australian Equity Funds
- Passive Australian Equity Funds
- Active Global Equity Funds
- Passive Global Equity Funds
- Sustainable Funds
- Emerging Market Equity Funds
- Passive Australian Listed Property Funds
- Active Australian Listed Property Funds
- Passive Global Infrastructure Funds
- Active Global Infrastructure Funds
- Active Global Property Funds
- Passive Global Property Funds
- Active Australian Fixed Interest Funds
- Passive Australian Fixed Interest Funds
- Active Global Fixed Interest Funds
- Passive Global Fixed Interest Funds
Markets
Index
|
Last price
|
Change
|
% Change
|
---|---|---|---|
All Ordinaries | 7,837.40 | 100.10 | -1.26% |
CAC 40 | 8,088.24 | 71.59 | 0.89% |
DAX 40 | 18,161.01 | 243.73 | 1.36% |
Dow JONES (US) | 38,239.66 | 153.86 | 0.40% |
FTSE 100 | 8,139.83 | 60.97 | 0.75% |
HKSE | 17,651.15 | 366.61 | 2.12% |
NASDAQ | 15,927.90 | 316.14 | 2.03% |
Nikkei 225 | 37,934.76 | 306.28 | 0.81% |
NZX 50 Index | 11,805.09 | 141.34 | -1.18% |
S&P 500 | 5,099.96 | 51.54 | 1.02% |
S&P/ASX 200 | 7,575.90 | 107.10 | -1.39% |
SSE Composite Index | 3,088.64 | 35.74 | 1.17% |
Market Movers
Name
|
Last price
|
Change
|
% Change
|
---|---|---|---|
Sayona Mining Ltd SYA | 0.03 | 0.00 | -2.94% |
The Star Entertainment Group Ltd SGR | 0.39 | 0.01 | -2.50% |
South32 Ltd S32 | 3.37 | 0.06 | 1.81% |
Tietto Minerals Ltd TIE | 0.68 | 0.00 | 0.00% |
Imugene Ltd IMU | 0.08 | 0.00 | -4.82% |
BHP Group Ltd BHP | 43.15 | 2.08 | -4.60% |
Jupiter Mines Ltd JMS | 0.30 | 0.01 | 1.69% |
Red 5 Ltd RED | 0.44 | 0.01 | 2.33% |
Telstra Group Ltd TLS | 3.64 | 0.03 | -0.82% |
Pilbara Minerals Ltd PLS | 3.80 | 0.06 | -1.55% |